Turn Fear Inside Out
In the last 10 years (1) the average cost to bring a product from discovery through to launch has basically doubled, (2) clinical trial enrollment durations have increased ~56%, (3) the success rate fell ~27%, and (4) the average peak sales per pipeline asset fell ~30%.
We as an industry have to be smarter across every dimension of the product lifecyle to increase the success rate for patients; patients like Karla who face down the fear and uncertainty throughout the diagnosis and treatment process.
As we go into the next decade, let us commit our best to creating products that turn fear inside out to create hope for patients through their trust in the safety, efficacy, purity and value of our products.
Karla's story: https://www.thisislivingwithcancer.com/content/karlas_story
Figure: Adapted from Atlas Venture "2024 Year in Review"